Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Phentermine-topiramate→

Phentermine Topiramate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
960078-81-3
PubChem CID
9848354
Molecular formula
C22H36N2O8S
Molecular weight
488.6 g/mol
Drug class
Fixed-dose anti-obesity combinationsympathomimetic anorectic plus anticonvulsant
Mechanism of action
Phentermine promotes hypothalamic catecholamine release and suppresses appetite. Topiramate contributes to appetite and satiety effects through multiple mechanisms, including modulation of GABAergic signalling, voltage-gated ion channels, glutamate receptors and carbonic anhydrase.
Indications / reported uses
  • Long-term adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults and eligible adolescents with obesity or overweight with weight-related comorbidities, according to the current product label.

Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022580s021lbl.pdf · https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=876bd763-13fa-481e-b579-c2fc44dbf3c2&type=display · FDA product information

Identification source: PubChem record (CID 9848354). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Fixed-dose anti-obesity combination; sympathomimetic anorectic plus anticonvulsant

Mechanism of action

Phentermine promotes hypothalamic catecholamine release and suppresses appetite. Topiramate contributes to appetite and satiety effects through multiple mechanisms, including modulation of GABAergic signalling, voltage-gated ion channels, glutamate receptors and carbonic anhydrase.

General use cases

  • Long-term adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults and eligible adolescents with obesity or overweight with weight-related comorbidities, according to the current product label.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Phentermine Topiramate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Phentermine Topiramate Permitted Daily Exposure (PDE) report (the Phentermine Topiramate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Phentermine Topiramate Occupational Exposure Limit (OEL) report (the Phentermine Topiramate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.